NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD shares have increased by 20.7% and is now trading at $207.82. View which stocks have been most impacted by Coronavirus.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) released its quarterly earnings data on Thursday, May, 7th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01. The medical instruments supplier had revenue of $198 million for the quarter, compared to analyst estimates of $189.61 million. Insulet had a net margin of 0.66% and a return on equity of 7.66%. The firm's quarterly revenue was up 23.8% on a year-over-year basis. During the same period last year, the firm earned $0.07 EPS. View Insulet's earnings history.

Insulet updated its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $210.792-217.877 million, compared to the consensus revenue estimate of $201.99 million.

19 brokerages have issued twelve-month price objectives for Insulet's stock. Their forecasts range from $140.00 to $250.00. On average, they expect Insulet's share price to reach $196.44 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View analysts' price targets for Insulet.

Headlines about PODD stock have trended neutral on Saturday, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.03%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%) and IBM Retirement Fund (0.00%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View institutional ownership trends for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, and IBM Retirement Fund. View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $207.82.

Insulet has a market capitalization of $13.11 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]